JP2013533286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533286A5 JP2013533286A5 JP2013521879A JP2013521879A JP2013533286A5 JP 2013533286 A5 JP2013533286 A5 JP 2013533286A5 JP 2013521879 A JP2013521879 A JP 2013521879A JP 2013521879 A JP2013521879 A JP 2013521879A JP 2013533286 A5 JP2013533286 A5 JP 2013533286A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- individual
- receptor agonist
- combinations
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 41
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 21
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 21
- 239000000018 receptor agonist Substances 0.000 claims description 15
- 229940044601 receptor agonist Drugs 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- YXEQXPNSBUIRDZ-OAQYLSRUSA-N 1-[5-[(3r)-3-amino-4-hydroxy-3-methylbutyl]-1-methylpyrrol-2-yl]-4-(4-methylphenyl)butan-1-one Chemical compound C1=CC(C)=CC=C1CCCC(=O)C1=CC=C(CC[C@@](C)(N)CO)N1C YXEQXPNSBUIRDZ-OAQYLSRUSA-N 0.000 claims description 6
- KIHYPELVXPAIDH-HNSNBQBZSA-N 1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 KIHYPELVXPAIDH-HNSNBQBZSA-N 0.000 claims description 6
- QDDQIPUKAXBMBX-UHFFFAOYSA-N 1-[[6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylic acid Chemical compound COC1=CC(CCC)=CC=C1COC1=CC=C(C(C)=C(CN2CC(C2)C(O)=O)CC2)C2=C1 QDDQIPUKAXBMBX-UHFFFAOYSA-N 0.000 claims description 6
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 claims description 6
- JRZJZOSWCNBQFS-NYYVNYEXSA-N 3-[[(1r)-1-[4-[5-[4-(2-methylpropyl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]ethyl]amino]cyclobutane-1-carboxylic acid Chemical compound C1=CC(CC(C)C)=CC=C1C1=NC(C=2C=CC(=CC=2)[C@@H](C)NC2CC(C2)C(O)=O)=NO1 JRZJZOSWCNBQFS-NYYVNYEXSA-N 0.000 claims description 6
- 229960000556 fingolimod Drugs 0.000 claims description 6
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 229940044551 receptor antagonist Drugs 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 4
- 229940127240 opiate Drugs 0.000 claims description 4
- 229950009275 ponesimod Drugs 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 150000003058 platinum compounds Chemical class 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 2
- 229960004528 vincristine Drugs 0.000 claims description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 2
- -1 ponecimod Chemical compound 0.000 claims 1
- 239000005557 antagonist Substances 0.000 description 13
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 108010035597 sphingosine kinase Proteins 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- WGSHXYXZHQJPQL-DMBFJYOSSA-N (E,16R,17S)-17-amino-16,18-dihydroxyoctadec-14-ene-1,1,1-tricarbaldehyde Chemical compound C(=O)C(CCCCCCCCCCCC/C=C/[C@H]([C@H](CO)N)O)(C=O)C=O WGSHXYXZHQJPQL-DMBFJYOSSA-N 0.000 description 1
- ZKVKFPZCVMFTCI-CWFJQSRLSA-N (E,3R,4R)-3-amino-2,4-dihydroxynonadec-5-enal Chemical compound C(=O)C(O)[C@H](N)[C@H](O)\C=C\CCCCCCCCCCCCC ZKVKFPZCVMFTCI-CWFJQSRLSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- YRXOQXUDKDCXME-QWKHPXNBSA-N n,n-dimethylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@H](O)[C@@H](CO)N(C)C YRXOQXUDKDCXME-QWKHPXNBSA-N 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36950410P | 2010-07-30 | 2010-07-30 | |
| US61/369,504 | 2010-07-30 | ||
| PCT/US2011/045236 WO2012015758A2 (en) | 2010-07-30 | 2011-07-25 | Methods of treating pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013533286A JP2013533286A (ja) | 2013-08-22 |
| JP2013533286A5 true JP2013533286A5 (enExample) | 2014-09-11 |
Family
ID=44543779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013521879A Pending JP2013533286A (ja) | 2010-07-30 | 2011-07-25 | 疼痛を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8747844B2 (enExample) |
| EP (1) | EP2598126A2 (enExample) |
| JP (1) | JP2013533286A (enExample) |
| WO (1) | WO2012015758A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2326621T (pt) | 2008-07-23 | 2016-09-12 | Arena Pharm Inc | Derivados de ácido 1,2,3,4-tetrahidrociclopenta[b]indol-3-il) acético substituídos úteis no tratamento de distúrbios autoimunes e inflamatórios |
| PT2342205T (pt) | 2008-08-27 | 2016-07-28 | Arena Pharm Inc | Derivados de ácido tricíclico substituído como agonistas de recetor s1p1 úteis no tratamento de distúrbios autoimunes e inflamatórios |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| WO2011109471A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| JP6124417B2 (ja) * | 2012-05-31 | 2017-05-10 | 学校法人近畿大学 | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤 |
| US20150087613A1 (en) * | 2013-09-26 | 2015-03-26 | Saint Louis University | Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| DK3310760T3 (da) | 2015-06-22 | 2022-10-24 | Arena Pharm Inc | Krystallinsk L-argininsalt af (R)-2-(7-(4-cyclopentyl-3-(trifluormethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)eddikesyre til anvendelse ved S1P1-receptor-associerede lidelser |
| EP3118621A1 (en) * | 2015-07-14 | 2017-01-18 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy |
| US10877045B2 (en) * | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| CN108024998A (zh) * | 2015-08-11 | 2018-05-11 | 阿卡制药有限公司 | 包含s1p受体调节剂的组合物 |
| CN108369222B (zh) | 2015-08-31 | 2021-06-04 | 明尼苏达大学董事会 | 阿片受体调节剂及其用途 |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| US11478448B2 (en) | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| BR112020024762A2 (pt) | 2018-06-06 | 2021-03-23 | Arena Pharmaceuticals, Inc. | métodos de tratamento de condições relacionadas ao receptor s1p1 |
| US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| US11497795B2 (en) | 2018-09-28 | 2022-11-15 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
| CN110511240B (zh) * | 2019-08-27 | 2022-03-08 | 南京医科大学 | 一种髓细胞触发受体2的内源性配体及其应用 |
| US11594117B2 (en) | 2020-12-18 | 2023-02-28 | Itron, Inc. | Network edge detection and notification of gas pressure situation |
| WO2022194941A1 (en) * | 2021-03-17 | 2022-09-22 | Actelion Pharmaceuticals Ltd | Pharmaceutical dosage system |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1073471B (de) | 1958-09-02 | 1960-01-21 | Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) | Verfahren zur Herstellung von Azelainsäure |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5583160A (en) | 1989-02-03 | 1996-12-10 | The Biomembrane Institute | Methylsphingosine used to treat apoptosis |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
| US5466716A (en) | 1990-12-31 | 1995-11-14 | The Biomembrane Institute | Liposomal trimethylsphingosine |
| US5248824A (en) | 1990-12-31 | 1993-09-28 | The Biomembrane Institute | Method of preparing N,N,N-trimethylsphingosine |
| US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5260288A (en) | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
| WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| CA2145641C (en) | 1992-12-03 | 2008-05-27 | Richard J. Gregory | Pseudo-adenovirus vectors |
| DK0695169T3 (da) | 1993-04-22 | 2003-03-17 | Skyepharma Inc | Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
| CN1263864C (zh) | 1993-10-25 | 2006-07-12 | 坎吉公司 | 重组腺病毒载体及其使用方法 |
| WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
| US5627171A (en) | 1994-04-11 | 1997-05-06 | Oncomembrane, Inc. | Sphingosine-1-phosphate/trimethylsphingosine composition |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| ATE381624T1 (de) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | Retrovirale vektoren mit verminderter rekombinationsrate |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| AUPO900297A0 (en) | 1997-09-08 | 1997-10-02 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| US6098631A (en) * | 1998-01-21 | 2000-08-08 | The Regents Of The University Of Michigan | Compositions and methods for treating autoimmune disease |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| ES2523856T3 (es) | 2000-12-22 | 2014-12-02 | Lpath, Inc. | Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos |
| JP4217620B2 (ja) * | 2001-09-27 | 2009-02-04 | 杏林製薬株式会社 | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 |
| EP1481680A1 (en) * | 2003-05-30 | 2004-12-01 | Aventis Pharma Deutschland GmbH | Use of S1P |
| EP1484057A1 (en) * | 2003-06-06 | 2004-12-08 | Aventis Pharma Deutschland GmbH | Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| CA2545582C (en) * | 2003-11-21 | 2013-04-16 | Actelion Pharmaceuticals Ltd | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| CN1921847B (zh) * | 2004-02-24 | 2010-06-16 | 三共株式会社 | 氨基醇化合物 |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| US8324237B2 (en) | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| JP2009526073A (ja) * | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| US7829674B2 (en) * | 2006-10-27 | 2010-11-09 | Lpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
| US8563594B2 (en) * | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
| WO2009074969A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Lausanne | Sphingosine-1-phosphate, analogs and antagonists for use as medicaments |
| WO2009124294A2 (en) * | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| RU2505527C2 (ru) * | 2008-08-12 | 2014-01-27 | Аллерган, Инк. | Антагонисты рецептора сфингозин-1-фосфата (s1p) и способы их применения |
-
2011
- 2011-07-25 WO PCT/US2011/045236 patent/WO2012015758A2/en not_active Ceased
- 2011-07-25 US US13/189,954 patent/US8747844B2/en active Active
- 2011-07-25 JP JP2013521879A patent/JP2013533286A/ja active Pending
- 2011-07-25 EP EP11745855.4A patent/EP2598126A2/en not_active Withdrawn
-
2014
- 2014-04-07 US US14/246,847 patent/US8945549B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533286A5 (enExample) | ||
| Vazzana et al. | Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems | |
| Hiranita et al. | Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats | |
| Donati et al. | Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis | |
| EA201400246A1 (ru) | Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости | |
| Turnaturi et al. | Multitarget opioid ligands in pain relief: New players in an old game | |
| PE20141171A1 (es) | Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| BR112013029126A2 (pt) | formas de dosagem farmacêuticas intranasais compreendendo naloxona | |
| PT2101740E (pt) | Nova composição farmacêutica não susceptível de abuso que compreende opióides | |
| JP2011521963A5 (enExample) | ||
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| MX2019009841A (es) | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. | |
| Christoph et al. | Spinal-supraspinal and intrinsic µ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice | |
| JP2017531023A (ja) | 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用 | |
| Bihel | Opioid adjuvant strategy: improving opioid effectiveness | |
| Kozela et al. | The effects of NMDA receptor antagonists on acute morphine antinociception in mice | |
| Oh et al. | Activation of protein kinase C is required for AMPA receptor GluR1 phosphorylation at serine 845 in the dorsal striatum following repeated cocaine administration | |
| WO2015059638A3 (en) | Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment | |
| EP4616915A3 (en) | Ecopipam for treatment of tourettes syndrome | |
| WO2017199140A1 (es) | Composición farmacéutica de una combinación de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor | |
| RU2010121765A (ru) | Средство для профилактики или лечения рака | |
| Girard et al. | Modulation of paracetamol and nefopam antinociception by serotonin 5-HT3 receptor antagonists in mice | |
| SI2849740T1 (en) | A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro (cyclohexane-1,1'-pyrano , 4, b) indol) -4-amine and paracetamol or propacetamol | |
| Viswanath et al. | Agonist treatment in opioid use: advances and controversy |